Partial
Needs Review
Patient Risk:
Moderate
Summary
Several safety/boxed-warning claims are consistent with the label, and core identity/mechanism/RA and UC indications are supported. However, multiple major claims are either not supported by the provided label content (e.g., blood clots, generic/patent assertions, Pfizer ownership/manufacturing) or are only partially supported (psoriatic arthritis population; patient counseling specificity), resulting in a partial overall alignment.
Category Scores
Accurate Statements
Xeljanz is also known by its generic name tofacitinib.
11 DESCRIPTION
Xeljanz is a Janus kinase (JAK) inhibitor.
11 DESCRIPTION; 12.1 Mechanism of Action
Xeljanz is used to treat rheumatoid arthritis in adults with moderately to severely active disease who have had an inadequate response or intolerance to one or more TNF blockers.
1 INDICATIONS AND USAGE (1.1 Rheumatoid Arthritis)
Xeljanz is used to treat ulcerative colitis in adults with moderately to severely active disease who have had an inadequate response or intolerance to one or more TNF blockers.
1 INDICATIONS AND USAGE (1.5 Ulcerative Colitis)
Tofacitinib works by blocking the activity of Janus kinases (JAKs).
12.1 Mechanism of Action
Janus kinases (JAKs) are enzymes involved in signaling pathways that regulate immune cell function and inflammation.
12.1 Mechanism of Action
Xeljanz carries a boxed warning regarding serious infections, including tuberculosis.
5 WARNINGS AND PRECAUTIONS (5.1 Serious Infections)
Xeljanz carries a boxed warning regarding serious infections, including invasive fungal infections.
5 WARNINGS AND PRECAUTIONS (5.1 Serious Infections)
Xeljanz carries an increased risk of stroke.
5.4 Major Adverse Cardiovascular Events
Xeljanz carries an increased risk of heart attack.
5.4 Major Adverse Cardiovascular Events
Xeljanz carries an increased risk of certain cancers.
5.3 Malignancy and Lymphoproliferative Disorders
Unsupported Statements
By inhibiting JAK signaling pathways, tofacitinib helps reduce inflammation.
Not explicitly supported in the provided label text for 12.1 (mechanism section provided does not state this outcome in the exact terms).
Tofacitinib helps reduce the symptoms associated with autoimmune diseases.
Not explicitly supported in the provided label text.
There are no generic versions of Xeljanz available in the United States.
Not addressed in the provided label sections.
The availability of generic versions of Xeljanz depends on patent expirations and ongoing legal challenges to those patents.
Not addressed in the provided label sections.
The original patents for tofacitinib are set to expire in the coming years.
Not addressed in the provided label sections.
The exact date for the launch of a generic tofacitinib can be influenced by litigation and regulatory approvals.
Not addressed in the provided label sections.
Xeljanz has several patents protecting its composition, method of use, and manufacturing processes.
Not addressed in the provided label sections.
The patents on Xeljanz are held by Pfizer.
Not addressed in the provided label sections.
Xeljanz is manufactured by Pfizer.
Not addressed in the provided label sections.
Xeljanz carries an increased risk of blood clots.
Not supported by the provided label text/citations included in the audit dataset.
Contradictions
Important Omissions
Psoriatic arthritis indication is incomplete: the label includes adult and pediatric patients 2 years of age and older for PsA (with the other provided limitations), while the claim restricts to adults.
Importance:
Moderate
The response does not include key label limitations of use for combinations (e.g., not recommended with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine for RA/PSA/UC).
Importance:
Moderate
No dosage and administration details (including dose-related boxed-warning context) are provided, despite the claims touching boxed-warning safety topics.
Importance:
Moderate
Patient counseling statement is overly general; the provided label section shown is limited (17 Patient Counseling Information advises reading FDA-approved patient labeling; other specific counseling elements are in warnings/precautions).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Major safety-related claim ('increased risk of blood clots') is not supported by the provided label text/citations, and some indication/population information is incomplete (PsA pediatric inclusion). Other key boxed-warning elements (serious infections including TB/invasive fungal infections; MACE components such as stroke/MI; malignancy) are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Several claims are absent from the provided label content (generic/patent assertions, Pfizer ownership/manufacturing), and one major safety claim ('blood clots') is not supported by the provided label citations; PsA population is incomplete (pediatric inclusion omitted).
Suggested Improvement
Limit claims to information explicitly present in the FDA label sections provided (indications, mechanism, and the cited boxed-warning items). Remove or qualify statements not supported by the label dataset (generic availability/patent status/manufacturer/patent ownership; blood clot risk). For PsA, include pediatric patients ≥2 years as per the label.